Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers

PURPOSE: Evogliptin (DA-1229) is a novel, potent, and selective dipeptidyl peptidase IV (DPP-IV) inhibitor in clinical development for the treatment of type 2 diabetes mellitus. This study aimed to investigate the pharmacokinetic and pharmacodynamic profiles and tolerability of evogliptin after repe...

Descripción completa

Detalles Bibliográficos
Autores principales: Gu, Namyi, Park, Min Kyu, Kim, Tae-Eun, Bahng, Mi Young, Lim, Kyoung Soo, Cho, Sang-Heon, Yoon, Seo Hyun, Cho, Joo-Youn, Jang, In-Jin, Yu, Kyung-Sang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4199987/
https://www.ncbi.nlm.nih.gov/pubmed/25336915
http://dx.doi.org/10.2147/DDDT.S65678

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4199987/
https://www.ncbi.nlm.nih.gov/pubmed/25336915
http://dx.doi.org/10.2147/DDDT.S65678

Ejemplares similares